MNDL Bio utilizes AI-driven computational models to optimize gene expression for recombinant protein production, significantly enhancing yield and reducing costs. The platform replaces traditional trial-and-error methods with precise, data-driven strain engineering, enabling faster time-to-market and improved sustainability in biotech and foodtech applications.
Funding
$2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Traditional methods of optimizing gene expression for recombinant protein production rely on trial-and-error, resulting in low yields, high costs, and extended development timelines. This inefficient process hinders innovation and sustainability in biotech and foodtech applications.
Solution
MNDL Bio offers an AI-driven computational platform that optimizes gene expression to enhance recombinant protein production. The platform employs advanced computational models spanning the entire gene expression process, including ORF, regulatory sequences, and vectors. By transitioning from trial-and-error to data-driven strain engineering, MNDL Bio enables precise strain engineering, leading to significantly improved protein production yield, reduced costs, and faster time-to-market. The technology has a proven track record across multiple hosts and dozens of recombinant proteins.
Target Audience
MNDL Bio's primary customers are companies in the biotech and foodtech industries seeking to improve recombinant protein production for various applications.
Features
- AI and deep learning algorithms for comprehensive gene optimization
- Advanced computational models spanning every stage of the gene expression process
- Host-tailored approach to gene optimization
- Optimization of ORF, regulatory sequences (promoters, UTRs), and vectors
- Data-driven strain engineering